9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
42 hedge funds and large institutions have $3M invested in 9 Meters Biopharma in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 38 closing their positions.
4,700% more call options, than puts
Call options by funds: $1.73M | Put options by funds: $36K
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
43% less funds holding
Funds holding: 74 → 42 (-32)
71% less capital invested
Capital invested by funds: $10.4M → $3M (-$7.4M)
79% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$95.4K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$57K |
| 3 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
+$54.2K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$42K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$37.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$196K |
| 2 |
RCM
Requisite Capital Management
Dallas,
Texas
|
-$65K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$51K |
| 4 |
VF
Virtu Financial
New York
|
-$49K |
| 5 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
-$45K |
NMTR Hedge Fund Activity: Q4 2022 in Review
42 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q4 2022, worth a combined $3M — down 71% from $10.4M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of NMTR and 8 opened new positions — a net loss of 30 holders — while 13 trimmed existing stakes and 14 added.
The largest buyer was HRT Financial, adding an estimated $95.4K. The largest seller was Ergoteles, exiting entirely with an estimated $196K sold.
- 42 institutional investors held 9 Meters Biopharma (NMTR) as of Q4 2022, down from 74 in Q3 2022.
- Funds reported $3M of 9 Meters Biopharma stock for Q4 2022, down 71% quarter-over-quarter.
- 8 funds opened new 9 Meters Biopharma positions in Q4 2022 and 38 closed out, a net change of -30 holders.
- The largest 9 Meters Biopharma buyer in Q4 2022 was HRT Financial, an estimated $95.4K added.
- The largest 9 Meters Biopharma seller in Q4 2022 was Ergoteles, an estimated $196K sold.
Based on aggregated 13F filings for Q4 2022.